SMECS
- Summary
- Small molecules for selective elimination of contaminating pluripotent stem cells from cultures of their differentiated Derivatives.
- Technology Benefits
- Compounds toxic against PSCs but not against differentiated derivatives
Compounds readily available
New route to cardiomyocytes
Useable in tissue repair
First in vitro results
- Technology Application
- The diamines exhibited high cytotoxicity to murine and human PSCs but not to CMs derived from these. They are suitable for the elimination of PSCs from differentiating derivatives that contain CMs, either in unpurified or pre-purified form. A further advantage of the diamines is that the compounds are readily available and show significantly higher PSC-specific cytotoxic activity in comparison to known small molecules.
- Detailed Technology Description
- a fundamental obstacle in the use of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) are contaminating undifferentiated PSCs that remain in the population of differentiated cells which carry the risk of tumour formation. PSC ablation by immunologic targeting is safe but less efficient because single-cell dissociation is required. In this regard, the most promising strategy is the selective chemical ablation of undifferentiated cells in PSC-derived populations using small molecules which are not toxic to differentiated cells of interest. The diamines of the general formula, particularly salicylic diamines, are capable of selectively eliminating PSCs from their differentiated derivatives.
- Type of Cooperation
- Licensing
- Application Date
- 06/11/2018 00:00:00
- Application No.
- WO2018EP80325 20181106
- Classes
- - international:
A61P9/00; C07C215/50; C07D209/14; C07D333/20; C12N5/071
- cooperative:
C07C215/50; C12N5/0081; C12N5/0657; C07C2601/14; C12N2501/999; C12N2506/02; C12N2506/45
- Others
- Patent application
- ID No.
- 4920
- Country/Region
- Germany
For more information, please click Here
